These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 2786289)
1. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289 [TBL] [Abstract][Full Text] [Related]
2. Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Muralidharan G; Hawes EM; McKay G; Midha KK Xenobiotica; 1991 Nov; 21(11):1441-50. PubMed ID: 1763518 [TBL] [Abstract][Full Text] [Related]
3. Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. Roy SD; Hawes EM; McKay G; Hubbard JW; Midha KK Can J Physiol Pharmacol; 1985 Jul; 63(7):778-81. PubMed ID: 3876145 [TBL] [Abstract][Full Text] [Related]
4. Kinetics of in vitro metabolism of methoxyphenamine in rats. Roy SD Xenobiotica; 1990 Jan; 20(1):55-70. PubMed ID: 2327108 [TBL] [Abstract][Full Text] [Related]
5. Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Muralidharan G; Hawes EM; McKay G; Korchinski ED; Midha KK Eur J Clin Pharmacol; 1991; 41(5):471-4. PubMed ID: 1761076 [TBL] [Abstract][Full Text] [Related]
6. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974 [TBL] [Abstract][Full Text] [Related]
7. Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. Roy SD; Hawes EM; Midha KK J Pharm Sci; 1987 Jun; 76(6):427-32. PubMed ID: 3625484 [TBL] [Abstract][Full Text] [Related]
8. Effect of sparteine and quinidine on the metabolism of methoxyphenamine by Cunninghamella bainieri. Foster BC; Wilson DL; McGilveray IJ Xenobiotica; 1989 Apr; 19(4):445-52. PubMed ID: 2750204 [TBL] [Abstract][Full Text] [Related]
9. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine. Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854 [TBL] [Abstract][Full Text] [Related]
10. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains. Al-Dabbagh SG; Idle JR; Smith RL J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757 [TBL] [Abstract][Full Text] [Related]
11. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Otton SV; Brinn RU; Gram LF Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945 [TBL] [Abstract][Full Text] [Related]
12. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Roy SD; Hawes EM; McKay G; Korchinski ED; Midha KK Clin Pharmacol Ther; 1985 Aug; 38(2):128-33. PubMed ID: 4017414 [TBL] [Abstract][Full Text] [Related]
13. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results. Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535 [TBL] [Abstract][Full Text] [Related]
14. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine. Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290 [TBL] [Abstract][Full Text] [Related]
15. Enantioselective gas chromatographic assays with electron-capture detection for methoxyphenamine and its three primary metabolites in human urine. Srinivas NR; Hubbard JW; Hawes EM; McKay G; Midha KK J Chromatogr; 1989 Jan; 487(1):61-72. PubMed ID: 2715275 [TBL] [Abstract][Full Text] [Related]
16. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro. Tyndale RF; Inaba T; Kalow W Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917 [TBL] [Abstract][Full Text] [Related]
17. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism. Roy SD; Hawes EM; Hubbard JW; McKay G; Midha KK Lancet; 1984 Dec; 2(8416):1393. PubMed ID: 6150386 [No Abstract] [Full Text] [Related]
18. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency. Dayer P; Kronbach T; Eichelbaum M; Meyer UA Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440 [TBL] [Abstract][Full Text] [Related]
19. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021 [TBL] [Abstract][Full Text] [Related]
20. In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Zysset T; Zeugin T; Küpfer A Biochem Pharmacol; 1988 Aug; 37(16):3155-60. PubMed ID: 3401246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]